Cargando…
Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446168/ http://dx.doi.org/10.1007/s40278-021-02435-5 |
Ejemplares similares
-
Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
Publicado: (2021) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)